


# Neurological Biomarkers Market Expected to Reach \$18.9 Billion by 2031 | Allied Market Research

WILMINGTON, DELAWARE, UNITED STATES, April 18, 2024

/EINPresswire.com/ -- size was valued at \$5.4 billion in 2021, and is estimated to reach \$18.9 billion by 2031, growing at a CAGR of 13.6% from 2022 to 2031. Ever-increasing rise in the incidence of Alzheimer's and Parkinson's is anticipated to contribute toward the robust growth of neurological biomarkers among these two applications. In addition, surge in adoption of neurological biomarkers in drug development and validation has increased over the years to improve the accuracy of clinical trials. Further, rise in transition toward personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimer's and Parkinson's.



**NEUROLOGICAL BIOMARKERS MARKET**  
OPPORTUNITIES AND FORECAST, 2021 - 2031

Neurological biomarkers market is expected to reach **\$18.9 Billion** in 2031  
Growing at a **CAGR of 13.6%** (2022-2031)

Neurological Biomarkers Market Report

□□□□ □□ □□□ □□□□□□□□ :

Neurobio, bioMérieux, PERKINELMER INC., shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix, MYRIAD RBM (MYRIAD GENETICS, INC.), Bio-Rad Laboratories, Inc., merck kgaa, darmstadt, germany, F. HOFFMANN-LA ROCHE LTD.

□□□□□□□□ □□□□□□ □□□□□□ <https://www.alliedmarketresearch.com/request-sample/3555>

On the basis of application of neurological biomarkers, the multiple sclerosis segment is expected to witness a significant CAGR during the forecast period. Rise in incidence rate of multiple sclerosis boot the growth of neurological biomarker market. For instance, according to National Multiple Sclerosis Society 2019, between 750,000 and 1 million people in the U.S. over the age of 18 are living with MS. There are more people living with MS in the Northeast and Midwest than in the South. The rates of MS have increased worldwide since 1955. The first

report of MS in the U.S. was published in 1976 and found 123,00 cases. A study from 1990 found 300,000 cases of MS. This compares to the estimated 750,000 to 1 million cases in 2019.

On the basis of region, Asia-Pacific is expected to witness highest CAGR during the forecast period in [neurological biomarkers market](#) forecast, owing to rise in geriatric population and the launch of various products in the region to fulfill the growing demands. Additionally, the development of human-induced pluripotent stem cells (iPS) for early diagnosis of Parkinson's disease in Japan is a recent trend, which is being followed. In addition, the rise in population in Japan is on an increase and the number has reached to 126.26 million individuals as of 2019. Therefore, such increase in population which is more susceptible to Parkinson's disease is anticipated to help supplement the neurological biomarkers industry growth.

For more information, visit <https://www.alliedmarketresearch.com/purchase-enquiry/3555>

However, the sales of neurological biomarkers product have witnessed hindrances, owing to the strict government regulations. The emerging ethical issues regarding early diagnosis of Alzheimer's disease, Parkinson's disease, and multiple Sclerosis is expected to impede the market growth. On the contrary, surge in healthcare investments in public as well as private sectors, increase in focus on developing cost-effective biomarker testing increase in patient population, and rise in demand for non-invasive diagnostic techniques for Alzheimer's and Parkinson's are anticipated to open new avenues for expansion of the neurological biomarkers market size during the forecast period.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

For more information, visit <https://www.alliedmarketresearch.com/library-access>

Neurological Biomarkers Market:

<https://www.alliedmarketresearch.com/neurological->

[biomarkers-market](#)

[Point of Care Diagnostics Market: https://www.alliedmarketresearch.com/point-of-care-diagnostics-market](#)

[Contraceptives Market: https://www.alliedmarketresearch.com/contraceptives-market](#)

[Electrophysiology Market: https://www.alliedmarketresearch.com/electrophysiology-devices-market](#)

□□□□ □□:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

□□□□□□ □□:

David Correa

Portland, OR, United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

[help@alliedmarketresearch.com](mailto:help@alliedmarketresearch.com)

Web: <https://www.alliedmarketresearch.com>

David Correa

Allied Market Research

+1 5038946022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/704633724>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.